<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022670</url>
  </required_header>
  <id_info>
    <org_study_id>R21HL107105</org_study_id>
    <nct_id>NCT02022670</nct_id>
  </id_info>
  <brief_title>Sodium Nitrite to Treat Arterial Aging</brief_title>
  <official_title>Clinical Translation of Nitrite Therapy to Treat Arterial Aging in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TheraVasc Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research will determine the effectiveness of nitrite, a naturally occurring
      compound in the body, for improving the health and function of arteries in middle-aged and
      older adults. The study also will provide insight into how sodium nitrite therapy improves
      artery health by determining the physiological mechanisms (biological reasons) involved.
      Overall, the proposed research will provide important new scientific evidence on the
      effectiveness of sodium nitrite for decreasing the risk of developing cardiovascular diseases
      with aging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The improvement in blood vessel function and stiffness will be determined over a 10 week
      period. Subjects will be randomly assigned to either placebo (0 mg/day), low dose (80 mg/day)
      or high dose (160 mg/day) sodium nitrite. Main outcome measures will be performed at baseline
      and week 10.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline and Week 10 Flow-Mediated Dilation</measure>
    <time_frame>Baseline (Week 0), Week 10</time_frame>
    <description>Brachial artery flow mediated dilation (FMD) is assessed prior to entering the study. If subjects pass the inclusion requirements, FMD is analyzed at baseline and week 10. Flow-Mediated Dilation is calculated as the percent change in artery diameter in response to 5 minutes of cuff occlusion at Baseline and Week 10 timepoints; i.e. (Peak Diameter-Baseline Diameter)/Baseline Diameter x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline and Week 10 Plasma Nitrite Concentrations</measure>
    <time_frame>Baseline (Week 0), Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Week 10 Aortic Pulse Wave Velocity</measure>
    <time_frame>Baseline (Week 0), Week 10</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Vascular Aging</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Nitrite 80 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Nitrite 160 mg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic sodium nitrite capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Nitrite</intervention_name>
    <description>80 mg/d or 160 mg/d</description>
    <arm_group_label>Sodium Nitrite 80 mg/d</arm_group_label>
    <arm_group_label>Sodium Nitrite 160 mg/d</arm_group_label>
    <other_name>TV1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50-79 years of age

          -  Ability to provide informed consent

          -  Score greater than 22 on the mini mental state exam

          -  Blood pressure greater than 100/60 mmHg for past 3 months

        Exclusion Criteria:

          -  Are taking any of the following medications/drugs: hormone replacement therapy,
             anti-hypertensives, nitrates, nervous system depressants, allopurinol,
             phosphodiesterase-5 inhibitors, blood thinners

          -  Are currently sick/have chronic clinical diseases such as kidney disease, diabetes, or
             unstable cardiovascular disease

          -  Are hypersensitive to nitrates or nitrites

          -  Have glucose-6-phosphate dehydrogenase deficiency

          -  Have blood methemoglobin greater than 2%

          -  Have a BMI greater than 40 kg/m^2

          -  Have a baseline FMD of greater than 6%

          -  Have not been post-menopausal for at least 1 year

          -  Perform regular vigorous aerobic/endurance exercise
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas R Seals, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison E DeVan, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.colorado.edu/intphys/research/cardiovascular.html</url>
    <description>Integrative Physiology of Aging Laboratory Website</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>March 12, 2015</results_first_submitted>
  <results_first_submitted_qc>June 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>flow-mediated dilation</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>sodium nitrite</keyword>
  <keyword>aging</keyword>
  <keyword>vascular diseases</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy men and women ages 50-79 years free of overt cardiovascular or chronic diseases.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
        </group>
        <group group_id="P2">
          <title>Sodium Nitrite 80 mg/d</title>
          <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
        <group group_id="P3">
          <title>Sodium Nitrite 160 mg/d</title>
          <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
        </group>
        <group group_id="B2">
          <title>Sodium Nitrite 80 mg/d</title>
          <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
        <group group_id="B3">
          <title>Sodium Nitrite 160 mg/d</title>
          <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="8"/>
                    <measurement group_id="B2" value="60" spread="6"/>
                    <measurement group_id="B3" value="64" spread="6"/>
                    <measurement group_id="B4" value="62" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline and Week 10 Flow-Mediated Dilation</title>
        <description>Brachial artery flow mediated dilation (FMD) is assessed prior to entering the study. If subjects pass the inclusion requirements, FMD is analyzed at baseline and week 10. Flow-Mediated Dilation is calculated as the percent change in artery diameter in response to 5 minutes of cuff occlusion at Baseline and Week 10 timepoints; i.e. (Peak Diameter-Baseline Diameter)/Baseline Diameter x 100.</description>
        <time_frame>Baseline (Week 0), Week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite 80 mg/d</title>
            <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Sodium Nitrite 160 mg/d</title>
            <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Week 10 Flow-Mediated Dilation</title>
          <description>Brachial artery flow mediated dilation (FMD) is assessed prior to entering the study. If subjects pass the inclusion requirements, FMD is analyzed at baseline and week 10. Flow-Mediated Dilation is calculated as the percent change in artery diameter in response to 5 minutes of cuff occlusion at Baseline and Week 10 timepoints; i.e. (Peak Diameter-Baseline Diameter)/Baseline Diameter x 100.</description>
          <units>%Change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.120" spread="0.528"/>
                    <measurement group_id="O2" value="4.307" spread="0.501"/>
                    <measurement group_id="O3" value="3.118" spread="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.740" spread="0.509"/>
                    <measurement group_id="O2" value="6.833" spread="0.785"/>
                    <measurement group_id="O3" value="4.609" spread="0.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Week 10 Plasma Nitrite Concentrations</title>
        <time_frame>Baseline (Week 0), Week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite 80 mg/d</title>
            <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Sodium Nitrite 160 mg/d</title>
            <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Week 10 Plasma Nitrite Concentrations</title>
          <units>micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.201" spread="0.066"/>
                    <measurement group_id="O2" value="0.209" spread="0.053"/>
                    <measurement group_id="O3" value="0.155" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.261" spread="0.051"/>
                    <measurement group_id="O2" value="0.412" spread="0.066"/>
                    <measurement group_id="O3" value="0.369" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline and Week 10 Aortic Pulse Wave Velocity</title>
        <time_frame>Baseline (Week 0), Week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
          </group>
          <group group_id="O2">
            <title>Sodium Nitrite 80 mg/d</title>
            <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
          <group group_id="O3">
            <title>Sodium Nitrite 160 mg/d</title>
            <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline and Week 10 Aortic Pulse Wave Velocity</title>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="782" spread="35"/>
                    <measurement group_id="O2" value="780" spread="55"/>
                    <measurement group_id="O3" value="946" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="774" spread="36"/>
                    <measurement group_id="O2" value="845" spread="75"/>
                    <measurement group_id="O3" value="942" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Sugar pill manufactured to mimic sodium nitrite capsules</description>
        </group>
        <group group_id="E2">
          <title>Sodium Nitrite 80 mg/d</title>
          <description>80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
        <group group_id="E3">
          <title>Sodium Nitrite 160 mg/d</title>
          <description>160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
Sodium Nitrite: 80 mg/d or 160 mg/d</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dizziness/light-headedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>asymptomatic orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Allison DeVan</name_or_title>
      <organization>University of Colorado Boulder</organization>
      <phone>303-735-6410</phone>
      <email>allison.devan@colorado.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

